Literature DB >> 33856641

Reflectance Confocal Microscopy Identification of Subclinical Basal Cell Carcinoma after Vismodegib Treatment: Report of a Case.

Alessia Villani1, Gabriella Fabbrocini2, Claudia Costa2, Massimiliano Scalvenzi2.   

Abstract

Although surgery represents the treatment of choice for the majority of basal cell carcinomas, different therapies are required to treat the advanced ones. Vismodegib and sonidegib are the two oral Smoothened (Smo) inhibitors approved for the treatment of advanced basal cell carcinoma. Clinical detection of subclinical basal cell carcinoma during and after vismodegib treatment could be difficult, requiring the use of dermoscopy and reflectance confocal microscopy as noninvasive diagnostic methods. We report the case of a 62-year-old woman with a locally advanced basal cell carcinoma successfully treated with vismodegib in which dermoscopy and reflectance confocal microscopy showed their superiority in detecting subclinical recurrent basal cell carcinoma developed on scar tissue after complete regression of the tumor.

Entities:  

Keywords:  Basal cell carcinoma; Dermoscopy; Nonmelanoma skin cancer; Reflectance confocal microscopy; Vismodegib

Year:  2021        PMID: 33856641     DOI: 10.1007/s13555-021-00533-9

Source DB:  PubMed          Journal:  Dermatol Ther (Heidelb)


  3 in total

1.  Basal cell carcinoma characterization using fusion ex vivo confocal microscopy: a promising change in conventional skin histopathology.

Authors:  J Pérez-Anker; S Ribero; O Yélamos; A García-Herrera; L Alos; B Alejo; M Combalia; D Moreno-Ramírez; J Malvehy; S Puig
Journal:  Br J Dermatol       Date:  2019-10-27       Impact factor: 9.302

2.  Tumor regrowth and development of keratinocytic neoplasms in patients under smoothened inhibition: in vivo assessment with reflectance confocal microscopy.

Authors:  I Alarcon; P Pasquali; J Malvehy; S Puig
Journal:  Skin Res Technol       Date:  2016-10-27       Impact factor: 2.365

3.  Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment.

Authors:  C Couzan; E Cinotti; B Labeille; P Vercherin; P Rubegni; F Cambazard; J L Perrot
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-09       Impact factor: 6.166

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.